Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAXNASDAQ:GLSINASDAQ:STOKNASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$11.66+5.9%$12.43$7.80▼$28.09$635.89MN/A641,882 shs1.59 million shsGLSIGreenwich LifeSciences$9.48-0.7%$9.62$8.06▼$18.75$126.73M1.6958,300 shs18,999 shsSTOKStoke Therapeutics$10.90$8.51$5.35▼$17.58$595.11M1.2704,657 shs333,419 shsVALNValneva$6.25+0.8%$6.53$3.62▼$9.16$522.73M1.8542,269 shs995 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics+11.21%+10.32%-24.07%-26.01%+1,100,999,900.00%GLSIGreenwich LifeSciences-0.93%-4.31%-4.40%-20.08%-31.74%STOKStoke Therapeutics+9.99%+18.74%+13.19%+33.58%-29.59%VALNValneva-3.28%-3.56%-5.63%-12.18%-31.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCAXBicara Therapeutics1.6783 of 5 stars3.50.00.00.01.40.80.6GLSIGreenwich LifeSciences2.1019 of 5 stars3.50.00.00.03.33.30.0STOKStoke Therapeutics3.8994 of 5 stars3.62.00.04.82.21.70.0VALNValneva2.5619 of 5 stars3.55.00.00.02.30.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 3.00Buy$31.86173.23% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00311.39% UpsideSTOKStoke Therapeutics 3.29Buy$23.20112.84% UpsideVALNValneva 3.00Buy$15.50148.00% UpsideCurrent Analyst Ratings BreakdownLatest GLSI, VALN, STOK, and BCAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025BCAXBicara TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$8.005/23/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.005/16/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $41.005/14/2025STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $35.005/8/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.004/17/2025BCAXBicara TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderweight$8.004/15/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/9/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/9/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.52 per shareN/ASTOKStoke Therapeutics$190.91M3.12N/AN/A$3.57 per share3.05VALNValneva$186.06M2.81N/AN/A$2.00 per share3.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara TherapeuticsN/AN/A0.00N/AN/AN/AN/AN/A6/26/2025 (Estimated)GLSIGreenwich LifeSciences-$8.89M-$1.26N/AN/AN/AN/A-185.12%-164.27%8/12/2025 (Estimated)STOKStoke Therapeutics-$104.70M$0.79N/AN/AN/A-629.90%-54.45%-40.77%8/5/2025 (Estimated)VALNValneva-$109.78M-$1.19N/AN/AN/A-4.35%-3.93%-1.42%8/12/2025 (Estimated)Latest GLSI, VALN, STOK, and BCAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/13/2025Q1 2025BCAXBicara Therapeutics-$0.40-$0.68-$0.28-$0.68N/AN/A5/7/2025Q1 2025VALNValneva-$0.40-$0.13+$0.27-$0.13$41.80 million$51.79 million4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/A3/27/2025Q4 2024BCAXBicara Therapeutics-$0.31-$0.39-$0.08-$0.39N/AN/A3/24/2025Q4 2024STOKStoke Therapeutics-$0.56-$0.18+$0.38-$0.18$4.20 million$22.61 million3/20/2025Q4 2024VALNValneva-$0.22-$0.54-$0.32-$0.54$55.64 million$56.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/AN/AN/AGLSIGreenwich LifeSciencesN/A6.916.91STOKStoke TherapeuticsN/A5.095.09VALNValneva0.702.782.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/AGLSIGreenwich LifeSciences4.16%STOKStoke TherapeuticsN/AVALNValneva11.39%Insider OwnershipCompanyInsider OwnershipBCAXBicara Therapeutics15.50%GLSIGreenwich LifeSciences51.67%STOKStoke Therapeutics11.30%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3254.54 millionN/AN/AGLSIGreenwich LifeSciences313.37 million6.35 millionNot OptionableSTOKStoke Therapeutics10054.60 million46.98 millionOptionableVALNValneva70083.64 million69.15 millionNot OptionableGLSI, VALN, STOK, and BCAX HeadlinesRecent News About These CompaniesValneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate UpdateJune 4 at 1:00 AM | globenewswire.comValneva (NASDAQ:VALN) Shares Gap Down - Time to Sell?June 3 at 12:52 PM | marketbeat.comValneva SE (NASDAQ:VALN) Sees Large Decrease in Short InterestJune 2 at 10:13 AM | marketbeat.comValneva to Participate at U.S. and European Investor Conferences in JuneMay 26, 2025 | globenewswire.comUS CDC accepts recommendations for chikungunya vaccinesMay 21, 2025 | msn.comLondon man among thousands who've rolled up their sleeves to trial Lyme disease vaccineMay 19, 2025 | cbc.caUS Advises Older Travelers to Avoid Chikungunya VaccineMay 16, 2025 | infectiousdiseaseadvisor.comFDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for SeniorsMay 15, 2025 | pharmexec.comFDA, CDC recommend pause in Valneva chikungunya vaccine for older adultsMay 14, 2025 | cidrap.umn.eduU.S. Advises Older Travelers to Avoid Chikungunya VaccineMay 13, 2025 | usnews.comFDA warns seniors to avoid this vaccine after deadly complicationsMay 13, 2025 | msn.com2VALN : US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For...May 13, 2025 | benzinga.comCOVID-19 fueled increase in hospital-onset MRSA, study findsMay 12, 2025 | cidrap.umn.eduFDA, EU Flag Safety Issues With Valneva’s Chikungunya VaccineMay 12, 2025 | biospace.comFDA follows EMA in limiting use of Valneva shotMay 12, 2025 | biopharmadive.comWhat Is the Chikungunya Vaccine? CDC Issues Notice to Older TravelersMay 12, 2025 | msn.comUS health officials advise older travelers not to get a chikungunya vaccineMay 12, 2025 | apnews.comValneva’s chikungunya vaccine use halted in older adults amid safety concernsMay 12, 2025 | finance.yahoo.comValneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United StatesMay 12, 2025 | globenewswire.comU.S. recommends a pause in Valneva chikungunya vaccine for those over 60May 10, 2025 | msn.comEli Lilly extends Purdue alliance; EMA investigates Valneva shotMay 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLSI, VALN, STOK, and BCAX Company DescriptionsBicara Therapeutics NASDAQ:BCAX$11.66 +0.65 (+5.90%) As of 01:20 PM EasternBicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Greenwich LifeSciences NASDAQ:GLSI$9.48 -0.07 (-0.73%) As of 12:47 PM EasternGreenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Stoke Therapeutics NASDAQ:STOK$10.90 0.00 (0.00%) As of 01:21 PM EasternStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Valneva NASDAQ:VALN$6.25 +0.05 (+0.81%) As of 01:11 PM EasternValneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
